Please assess the completion status of the following clinical trial:

Trial Title: A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects aged 6 to 17 years old~* Subjects with stable neurological disease and neurogenic detrusor overactivity~* Subjects using clean intermittent catheterization may participate~Exclusion Criteria:~* Concomitant medications which may increase the risk to subjects or confound study results~* Other medical conditions which may increase the risk to subjects or confound study results~* Contraindications to the use of fesoterodine or oxybutynin

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Fesoterodine PR 4 mg (Type: EXPERIMENTAL): Fesoterodine PR 4 mg for 12 weeks in active comparator period, followed by 12 weeks in safety extension period
- Fesoterodine PR 8 mg (Type: EXPERIMENTAL): Fesoterodine 8 mg for first week followed by 11 weeks at 8 mg in active control period, followed by 12 weeks in safety extension period.
- Oxybutynin (Type: ACTIVE_COMPARATOR): Oxybutynin
- Fesoterodine BIC 2 mg (Type: EXPERIMENTAL): Fesoterodine BIC 2 mg for 12 weeks in efficicay period, followed by 12 weeks in safety extension period.
- Fesoterodine BIC 4 mg (Type: EXPERIMENTAL): Fesoterodine BIC 4 mg for first week followed by 11 weeks at 8 mg in the efficacy period, followed by 12 weeks in safety extension period.

Based on this trial design, predict the completion outcome and termination type (if applicable).